NCT04616729View on ClinicalTrials.gov

DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions
Breast Cancer Female
Interventions
DRUG

Triptorelin 3.75 MG Injection

Depot Group (Group A) will receive Triptorelin 3.75mg Depot form for final oocyte maturation.

PROCEDURE

Transvaginal oocyte retrieval

Patients in both groups will undergo a transvaginal oocyte retrieval after ovarian stimulation.

DRUG

Triptorelin Injection

Daily Group (Group B) will receive Triptorelin 0.2mg Daily form for final oocyte maturation.

Trial Locations (2)

3000

NOT_YET_RECRUITING

Universitaire Ziekenhuizen Leuven, Leuven

3190

RECRUITING

Universitair Ziekenhuis Brussel, Boortmeerbeek

All Listed Sponsors
collaborator

Universitaire Ziekenhuizen KU Leuven

OTHER

lead

Universitair Ziekenhuis Brussel

OTHER